Umbilical cord mesenchymal stem cells combined with autologous platelet-rich plasma for lower extremity venous ulcers: A case report and literature review
Linlin Jiao,Jing Nie,Limei Duan,Xiaoping Qiao,Yuanda Sui
DOI: https://doi.org/10.1097/md.0000000000040433
IF: 1.6
2024-11-13
Medicine
Abstract:Lower extremity venous ulcer (LEVU) is a serious and refractory manifestation of chronic venous insufficiency of the lower extremities. The incidence rate among the general population is as high as 1.1% to 1.8%. [ 1 , 2 ] The pathological and physiological basis of venous ulcers is lower limb venous hypertension, which can be caused by either obstructed venous reflux or venous reflux. [ 3 , 4 ] Patients often experience swelling, dampness, and decay in their calves and ankles, with foul-smelling pus and dirty gray decaying material covering the wounds. Over the years, wounds have been difficult to close, and even if closed, patients are prone to recurrence, seriously affecting patients' physical and mental health and daily life. [ 5 , 6 ] Most patients require long-term treatment, wound cleaning, and dressing changes, which impose a serious economic and psychological burden and result in poor treatment outcomes. [ 7 , 8 ] Therefore, promoting ulcer recovery and shortening treatment time are now becoming the focus of clinical research. At present, nonsurgical therapies, including traditional Chinese medicine, physical therapy, and cytokine therapy, are commonly used for the treatment of lower limb venous ulcers. However, the results of clinical studies on lower limb venous ulcers in the literature are not consistent. [ 9 , 10 ]
medicine, general & internal